Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06138028

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Metastatic Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:
The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma

Clinical Trial Summary

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06138028
Study type Interventional
Source Qingdao Central Hospital
Contact
Status Recruiting
Phase Phase 2/Phase 3
Start date September 20, 2023
Completion date October 31, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01142388 - Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT05512520 - Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003） Phase 2
Active, not recruiting NCT05142709 - Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Completed NCT06190652 - Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Not yet recruiting NCT05522894 - AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC Phase 2
Completed NCT01472419 - Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma N/A
Enrolling by invitation NCT03800953 - The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Recruiting NCT04949256 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) Phase 3
Recruiting NCT05978193 - Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05760391 - A Study of IO Plus Radiotherapy in Patients With Advanced ESCC. N/A
Active, not recruiting NCT04460937 - Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Phase 1